|
|
| |
- The Company opened its laboratories in Seattle in 2006
- The Company holds a worldwide, exclusive Technology License Agreement from the University of Michigan
- Ten years of basic research done at the University of Michigan
- Patents issued in the USA and Europe
- More than 50 peer-reviewed scientific papers published on the technology
- More than $11,000,000 invested in the technology
- Spectrum of diseases as targets for the Company's products:
|
| |
|
- Vaccines
- Therapeutics
- Diagnostics
- Protein Production
|
| |
- In excess
of one billion dollar global market for initial target products:
|
| |
|
- Vaccines against bioterorism targets
- Infectious Diseases
- Certain cancers
|
| |
- Novel vaccines: Stimulate Cell-Mediated Immunity
- Experienced management; key researchers signed; advisors internationally recognized
|
|
|
